Association of body mass and systemic immune-inflammation indices with endocrine therapy resistance in luminal breast cancers

Abstract

Objective To explore correlations between body mass index (BMI), preoperative systemic immune-inflammation index (SII) and endocrine therapy resistance, and evaluate BMI and SII as predictors of resistance, in patients with luminal breast cancer. Methods This retrospective study included patients with luminal breast cancer who underwent endocrine therapy at Hebei General Hospital. Relationships between BMI and SII subgroups, and clinicopathological parameters were analysed using χ2-tests. Disease-free survival was assessed using Log-rank statistics. Multivariate analysis of factors related to disease progression were analysed using Cox proportional hazards model. Results Out of 161 patients, those with normal BMI and low SII had significantly lower endocrine resistance rates versus those with high BMI and SII, and BMI was significantly positively correlated with SII. High BMI or SII was associated with significantly lower disease-free survival rates. Hazard ratios for disease progression risk were 6.036, 3.508 and 1.733, for SII, BMI and TNM stage, respectively. Conclusion In patients with luminal breast cancer, high BMI (>23 kg/m2) and SII (>518 × 109/L) levels may predict high endocrine resistance rates. BMI, SII and TNM stage were independent prognostic factors for endocrine therapy resistance.

Prognostic prediction of systemic immune-inflammation index for patients with gynecological and breast cancers: a meta-analysis

“…The endpoint was OS in eight studies and PFS/DFS in six studies. Furthermore, the association of the SII index with LNM and LVI was also reported in five [11,13,14,21,22] and two [14,22] studies, respectively. All these studies were retrospectively performed in China (n = 6), Italy (n = 1), USA (n = 1), or Spain (n = 1).…”

“…No additional records were identified through manual searching. Finally, 9 published articles involving 2724 patients were included in this meta-analysis [11][12][13][14][15][16][20][21][22]. Among these 9 studies, two [11,14] contained the training and validation cohorts from different hospitals, and thus, 11 datasets were totally used for statistical analysis (Table 1).…”

“…Among these 9 studies, two [11,14] contained the training and validation cohorts from different hospitals, and thus, 11 datasets were totally used for statistical analysis (Table 1). Two studies [14,20] evaluated the relationship between SII index and prognosis in cervical cancer patients, five [12,13,16,21,22] focused on breast cancer, and two [11,15] investigated ovarian cancer. In the study of De Giorgi et al, triple-negative, HER2+, and HER2-ER+ subtypes of breast cancer were also independently analyzed, in addition to the overall results [16]; while all the other studies [12,13,21,22] on breast cancer only focused on specific breast cancer subtypes.…”

Prognostic value of the systemic immune-inflammation index in patients with breast cancer: a meta-analysis

“…The SII has been used to evaluate the pretreatment balance between inflammatory factors and immune status of patients with cancer [5][6][7][8]. The SII is associated with the prognosis of patients with breast cancer, although the results are controversial [9][10][11][12][13][14][15][16]. Therefore, we performed the current meta-analysis to identify the prognostic impact of the SII in patients with breast cancer by aggregating all available data.…”

<p>The Research Progress on the Prognostic Value of the Common Hematological Parameters in Peripheral Venous Blood in Breast Cancer</p>

“…Recent epidemiological and clinical studies have found that inflammatory responses are associated with breast tumors. 6,7 Inflammation constitutes part of the tumor microenvironment, and changes in inflammatory cells affect tumor progression, including breast cancer cell proliferation, invasion, decreased immunity, metastasis, and so on. 8,9 Tumor inflammatory response may be a potential target for treating tumors.…”